Skip to NavigationSkip to content

News

Throughout 2017, it has emerged that the FDA has issued a record low number of warning letters to pharmaceutical firms over misrepresentation of...
Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary endpoint of...
Only last month, the story broke that Teva was looking to cut away a number of employees, the rumours have now intensified with reports...
PhRMA has launched a lawsuit agaisnt the state of California over a new law which requires drugmakers to notify the state and health insurers of...
Bob Kerslake, now former chair of King’s College hospital, London, has handed in his resignation, citing the lack of long-term planning for the NHS...
Despite us nearing the end of the year, the news has not been slowing down at all. Headlines across Europe have been dominated by Brexit negotiations...
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-...
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly to establish bolt-on...
Since Sanofi released further data from a six-year study which showed that the risk of a severe dengue reaction is increased when its Dengvaxia...
Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder were positive, sending the...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches